News & Stories

See the latest news about CMT drug development and read stories from the CMT community that highlight why we must deliver treatments and cures during our lifetime.

Augustine Therapeutics Raises $18.5 Million in a Series A First Closing

Jun 26, 2024 | CMT Research Updates, CMTRF Funded Research

The Charcot-Marie-Tooth Research Foundation participated in the $18.5 million Series A funding round recently announced by Augustine Therapeutics. The financing was led by Asabys Partners, with the participation of Eli Lilly & Company, CMTRF, and current investors...

CMT Research Foundation Invests in ReviR Therapeutics Research to Pioneer Small Molecule Therapeutics for CMT1A

Jun 19, 2024 | CMT Research Updates, CMTRF Funded Research

The CMT Research Foundation has formed a strategic partnership with ReviR Therapeutics to advance small molecule therapeutics that modulate the expression of the gene that causes CMT1A. ReviR Therapeutics is developing a class of drugs called small molecule splice...

NMD Pharma Receives FDA Clearance to Initiate Clinical Trial of NMD670 for CMT

Jun 18, 2024 | CMT Research Updates, Drug Development

NMD Pharma recently announced that it has received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial of NMD670 in patients living with CMT types 1 and 2. NMD670 is a...

CMT Research Foundation to Benefit from a Portion of Ticket Sales from Alan Jackson’s 2024-2025 LAST CALL: ONE MORE FOR THE ROAD TOUR

May 30, 2024 | Press Releases

The CMT Research Foundation (CMTRF), the only nonprofit organization focused solely on delivering treatments and cures for Charcot-Marie-Tooth disease* (CMT), is pleased to announce support from Alan Jackson's LAST CALL ONE MORE FOR THE ROAD TOUR 2024-2025 dates....

CMTRF at the 2024 American Society of Gene and Cell Therapy Conference

May 9, 2024 | CMT Research Updates

We are thrilled to see that two CMTRF-funded projects were selected to present their advancements on their CMT gene therapy projects at the ASGCT conference, the premier conference for emerging genetic therapies. Dr. Lindsay Wallace presented a poster on the CMT1A...

CMT Research Foundation Invests in Project to Test if a Commercially Available Drug is Effective Treatment for X-linked Charcot-Marie-Tooth Disease

Apr 23, 2024 | CMT Research Updates, CMTRF Funded Research, Press Releases, Research News

The CMT Research Foundation (CMTRF), a non-profit focused solely on delivering treatments and cures for Charcot-Marie-Tooth disease (CMT), has invested in a project led by Dr. Charles Abrams, a Professor in the Department of Neurology and Rehabilitation at the...

The CMT Research Foundation Makes Leadership Changes to Drive Next Phase of Growth; Names Peter de Silva as Board Chair

Apr 11, 2024 | Press Releases

At its recent annual meeting, The CMT Research Foundation (CMTRF), a patient-led non-profit focused on delivering treatments and cures for Charcot-Marie-Tooth disease* made changes in its leadership to support the next phase of the Foundation’s growth. The Foundation...

Dr. Riann Egusquiza Joins The CMT Research Foundation as Director of Research

Apr 8, 2024 | About CMT, Press Releases

Riann Egusquiza (ryan egg-uh-ski-tha) PhD has joined The CMT Research Foundation as Director of Research, a newly created position. She will report to Cleary Simpson, CMTRF’s CEO, and be responsible for overseeing all CMTRF-funded research and scientific programming...

CMT Research Foundation Partners with Jenny Decker, CMT Patient Attempting to Solo-Circumnavigate Globe to Raise Awareness of Charcot-Marie-Tooth Disease

Apr 2, 2024 | Press Releases

The CMT Research Foundation (CMTRF) a non-profit focused solely on delivering treatments and cures for Charcot-Marie-Tooth disease (CMT)*, has partnered with Jenny Decker, a 40-year-old nurse battling CMT, a rare neurological disease with no known cure, who last...

CMT Research Update/NMD Pharma

Apr 1, 2024 | CMT Research Updates, Drug Development, Research News

NMD Pharma recently published data demonstrating that their drug candidate, NMD670, improves muscle function and neuromuscular transmission deficits in both animal models and patients. Dr. William David Arnold, a member of the CMTRF Scientific Advisory Board, who was...